We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $767M
1-Year Est. Return 119.71%
This Fund
S&P 500
This Quarter Est. Return
+8.44%
1 Year Est. Return
+119.71%
3 Year Est. Return
+244.81%
5 Year Est. Return
+382.5%
10 Year Est. Return
+2,655.81%
AUM
$1.48B
AUM Growth
+$175M
Cap. Flow
-$85.7M
Cap. Flow %
-5.8%
Top 10 Hldgs %
38.11%
Holding
211
New
41
Increased
36
Reduced
32
Closed
77

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$10.3M
2
IOVA icon
Iovance Biotherapeutics
IOVA
+$9.84M
3
HOWL icon
Werewolf Therapeutics
HOWL
+$9.68M
4
ALT icon
Altimmune
ALT
+$9.34M
5
TWLO icon
Twilio
TWLO
+$9.2M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$49.7M
2
ABBV icon
AbbVie
ABBV
+$26.3M
3
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$12.9M
4
BMY icon
Bristol-Myers Squibb
BMY
+$12.6M
5
PANW icon
Palo Alto Networks
PANW
+$10.4M

Sector Composition

Rank Sector Weight
1 Healthcare 55.27%
2 Miscellaneous 26%
3 Technology 8.46%
4 Industrials 5.02%
5 Financials 2.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.6B
$84.6M 5.72%
+625,000
New +$82.2M
AZN icon
2
AstraZeneca
AZN
$257B
$68.7M 4.65%
573,837
+93,600
+19% +$10.3M
JNJ icon
3
Johnson & Johnson
JNJ
$649B
$66.8M 4.52%
405,608
-48,292
-11% -$7.99M
MRK icon
4
Merck
MRK
$363B
$60.1M 4.06%
772,601
-75,030
-9% -$5.58M
MRK icon
5
PUT
Merck
MRK
$363B
$60.1M 4.06%
+772,600
New +$57.5M
XENE icon
6
Xenon Pharmaceuticals
XENE
$5.52B
$51.4M 3.48%
+276,130
New +$5.09M
SNY icon
7
Sanofi
SNY
$103B
$44.4M 3%
843,400
-154,500
-15% -$8.06M
GNRC icon
8
Generac Holdings
GNRC
$12.2B
$43.3M 2.93%
104,363
-1,300
-1% -$436K
ENPH icon
9
CALL
Enphase Energy
ENPH
$4.79B
$42.2M 2.86%
230,000
– –
LLY icon
10
Eli Lilly
LLY
$1.02T
$41.7M 2.82%
181,895
-247,305
-58% -$49.7M
ABBV icon
11
AbbVie
ABBV
$464B
$41.2M 2.79%
366,194
-233,306
-39% -$26.3M
IGV icon
12
PUT
iShares Expanded Tech-Software Sector ETF
IGV
$13.9B
$41M 2.77%
525,000
+170,500
+48% +$12.4M
XLK icon
13
PUT
State Street Technology Select Sector SPDR ETF
XLK
$122B
$31M 2.1%
+420,000
New +$29.4M
IWM icon
14
PUT
iShares Russell 2000 ETF
IWM
$77.2B
$24.1M 1.63%
105,000
-105,000
-50% -$23.6M
CCCC icon
15
C4 Therapeutics
CCCC
$421M
$19.6M 1.33%
518,611
+21,475
+4% +$769K
FVRR icon
16
CALL
Fiverr
FVRR
$318M
$19.2M 1.3%
79,000
-21,000
-21% -$4.36M
NICE icon
17
Nice
NICE
$6.21B
$19M 1.29%
76,786
+37,305
+94% +$8.59M
TEVA icon
18
CALL
Teva Pharmaceutical Industries Limited
TEVA
$45.8B
$18.9M 1.28%
1,910,000
+1,021,200
+115% +$10.8M
TAN icon
19
CALL
Invesco Solar ETF
TAN
$989M
$18.8M 1.27%
+210,000
New +$17.1M
EPIX
20
DELISTED
ESSA Pharma
EPIX
$18.5M 1.25%
648,303
+179,062
+38% +$5.2M
KRNT icon
21
Kornit Digital
KRNT
$664M
$18.4M 1.24%
147,793
-588
-0.4% -$62.1K
MSFT icon
22
Microsoft
MSFT
$3.68T
$18.3M 1.24%
67,536
– –
KURA icon
23
Kura Oncology
KURA
$1.05B
$18.1M 1.23%
868,886
+151,135
+21% +$3.75M
ZLAB icon
24
Zai Lab
ZLAB
$2.9B
$17.3M 1.17%
97,946
+32,158
+49% +$5.17M
BIIB icon
25
CALL
Biogen
BIIB
$32.2B
$17.3M 1.17%
+50,000
New +$15.1M
1
2 3 4 5

Similar funds

ISWM
Independent Solutions Wealth Management Williamsville, New York $766M AUM 31.53% 1-Year Est. Return
ACP
Albar Capital Partners London, United Kingdom $767M AUM 61.96% 1-Year Est. Return
NIM
Nexus Investment Management Toronto, Ontario, Canada $767M AUM 30.97% 1-Year Est. Return
ACM
Arvin Capital Management Austin, Texas $766M AUM 36.51% 1-Year Est. Return
CBT
Crews Bank & Trust Wauchula, Florida $766M AUM 19.5% 1-Year Est. Return
SPIA
Strategic Point Investment Advisors Providence, Rhode Island $767M AUM 17.58% 1-Year Est. Return
CNB
Camden National Bank Camden, Maine $767M AUM 14.32% 1-Year Est. Return
HI
Hendershot Investments Centreville, Virginia $766M AUM 10.81% 1-Year Est. Return

Sphera Funds Management's Q2 2021 Portfolio in Review

As of Q2 2021, Sphera Funds Management held 211 positions worth $1.48B, up 13% from $1.3B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Sphera Funds Management withdrew a net $85.7M in Q2 2021, closing 77 positions and reducing 32 holdings. Its most notable exit was Bristol-Myers Squibb, an estimated $12.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 55% of assets, down from 63% a quarter earlier, followed by Miscellaneous and Technology.

Against the trend, Sphera Funds Management opened a new position in Iovance Biotherapeutics worth $9.85M.

  • Sphera Funds Management's largest Q2 2021 buy was Iovance Biotherapeutics: 378,642 shares worth $9.85M.
  • Sphera Funds Management added most to AstraZeneca in Q2 2021, an estimated $10.3M increase.
  • Sphera Funds Management's biggest Q2 2021 reduction was Eli Lilly, cutting an estimated $49.7M.
  • Sphera Funds Management fully exited Bristol-Myers Squibb in Q2 2021, selling an estimated $12.6M.
  • Sphera Funds Management's ten largest holdings make up 38% of its $1.48B portfolio in Q2 2021.
  • Sphera Funds Management opened 41 new positions and closed 77 in Q2 2021.
  • Sphera Funds Management's portfolio value rose 13% quarter-over-quarter to $1.48B.

Based on Sphera Funds Management's 13F filing for Q2 2021, filed 17 Aug 2021.